Sunday , January 17 2021

The Diagnostic Drug offers significant protection against heart failure: studies, news and stories about Singapore



The drug sold here can lead to better life quality for 450,000 diabetics in Singapore after being found to significantly protect against heart failure.

A large clinical trial of AstraZeneca Forxiga, one of the three SGLT2 inhibitors (sodium glucose transporter) market, has shown a decrease in hospitalization for heart failure in diabetics by 17 percent.

The results of research by more than 17,000 diabetics in 33 countries over the age of 4.2 were published last Saturday, the first day of a three-day scientific meeting of the American Heart Association in Chicago.

Diabetes sufferers have far greater risk of heart failure than white ones, and the disease often leads to their hospitalization multiple times.

Dr. Peter Yan, a private practice cardiologist, told The Straits Times that treating asthma with diabetes risks heart failure compared to white people. Six in 10 patients have some form of diabetes.

The study showed that Forxigan – also known as Dapagliflozin – was able to assist both diabetics who are already suffering from heart failure and those who do not.

Diabetes sufferers have far greater risk of heart failure than white ones, and the disease often leads to their hospitalization multiple times.

For those with heart failure, hospitalization has decreased by 21 percent.

Generally, about 70 percent of diabetics get heart failure within five years of diagnosing diabetes, although some may not show any symptoms.

For non-heart failure diabetics, Forxiga reduced the incidence of hospitalization by 16 percent.

Forxiga, an oral remedy used to control blood sugar levels, is subsidized under the Medical Assistance Fund of the Ministry of Health.

Patients can also use Medisave in an outpatient program to chronically treat the disease to pay for the drug.

One tablet Dapagliflozin costs $ 1.36 before the subsidy, with shaving subsidies of up to half to three quarters of the cost.

Dr. Stanley Liew, an endocrinologist at Raffles Hospital, said the trial showed that the drug "resulted in lower rates of hospitalization for heart failure." We should consider using this drug in those who do not have heart failure to prevent the disease. "

He said the drug "helps address important medical needs among diverse types of diabetes type 2, reduced hospitalization or cardiovascular deaths, with a security profile that supports widespread use."

Professor Tan Huay Cheem, Director of the Heart Center Singapore Center National Center, welcomed the results.

He pointed out that since heart failure is more frequent in diabetics than heart attack, everything that can prevent the condition is good.

He said that diabetics are 1.5 times more likely to die from heart failure than diabetes.

Prof Tan added that compared to non-diabetic people, diabetic men are 2.4 times more likely to get heart failure, while diabetic women face five times the risk.

Dr. Yan said both endocrinologists and cardiologists agreed that Forxigan could help most diabetics.

He said: "The SGLT2 inhibitor class is very powerful in reducing heart failure hospitalization and appears to be independent of glucose control."

The drug could also reduce kidney disease by 24 percent. But it could not show better prevention of cardiovascular deaths, stroke or heart attacks in diabetics.


Source link